# A Randomised, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder

> **NCT00880048** · PHASE2 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 343 (actual)

## Conditions studied

- Depressive Disorder

## Interventions

- **DRUG:** orvepitant
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00880048
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-03-11
- **Primary completion:** 2010-06-21
- **Final completion:** 2010-06-21
- **Target enrollment:** 343 (ACTUAL)
- **Why stopped:** To allow assessment of isolated events of seizure during program
- **Last updated:** 2017-10-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00880048

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00880048, "A Randomised, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00880048. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*